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Abstract
This study identifies metabolic and protein phenotypic alterations in gastrocnemius, tibialis anterior and diaphragm muscles
of Col6a12/2 mice, a model of human collagen VI myopathies. All three muscles of Col6a12/2 mice show some common
changes in proteins involved in metabolism, resulting in decreased glycolysis and in changes of the TCA cycle fluxes. These
changes lead to a different fate of a-ketoglutarate, with production of anabolic substrates in gastrocnemius and tibialis
anterior, and with lipotoxicity in diaphragm. The metabolic changes are associated with changes of proteins involved in
mechanotransduction at the myotendineous junction/costameric/sarcomeric level (TN-C, FAK, ROCK1, troponin I fast) and in
energy metabolism (aldolase, enolase 3, triose phosphate isomerase, creatine kinase, adenylate kinase 1, parvalbumin, IDH1
and FASN). Together, these change may explain Ca2+ deregulation, impaired force development, increased muscle-
relaxation-time and fiber damage found in the mouse model as well as in patients. The severity of these changes differs in
the three muscles (gastrocnemius,tibialis anterior,diaphragm) and correlates to the mass-to-tendon (myotendineous
junction) ratio and to muscle morphology.
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Introduction
Collagen VI is an extracellular matrix (ECM) protein that
provides a structural link between ECM and the cell basement
membranes [1]. In skeletal muscle, the ECM-basement membrane
complex acts as a sensor that transfers the contractile force from
the sarcomere to cells and ultimately to the tendon [2] translating
extracellular mechanical stimuli into intracellular biochemical
signals (mechanotransduction) [3–6]. Defects in the ECM can
produce altered mechanosensing triggering the onset of diseases,
like dystrophies [5,7].
In humans, mutations in any of the three genes coding for
collagen VI (COL6A1, COL6A2, COL6A3) result in defective ECM
composition and cause a wide clinical spectrum of collagen VI
myopathies including Ullrich congenital muscular dystrophy
(UCMD), Bethlem myopathy (BM) [8–11] and myosclerosis
myopathy [12]. Collagen VI myopathies are characterized by
muscle weakness and contractures, associated with variable
degrees of joint hyperlaxity. UCMD, the most severe form of
collagen VI disorders, is characterized by early onset and proximal
joint contractures associated with striking distal hyperlaxity. The
orthopedic deformities and respiratory impairment, with dia-
phragm failure, generally develop within the first decade of life and
are life-threatening in the most severe cases [13–16]. A milder
form of human collagen VI myopathy is BM, characterized by
early contractures of finger flexors, wrist, elbows and ankles.
Respiratory failure and distal hyperlaxity are usually absent or are
milder than in UCMD, although the latter may occur only in very
young children with BM [8,17–19].
Although the link between altered ECM and muscle fiber
degeneration is not yet completely understood, the generation of a
mutant mouse with targeted inactivation of the Col6a1 gene
(Col6a12/2) provided a valuable tool for a better understanding of
the pathophysiology of collagen VI myopathies [20–22]. Col6a12/
2 mice carry a targeted inactivation of the a1 chain of collagen VI
and exhibit an early onset myopathic phenotype that is
reminiscent of features present in human BM and UCMD [20].
Studies in collagen VI null mice revealed that a cell pathway
involved in these myopathies includes an increased opening of the
permeability transition pore (PTP) within the mitochondrial inner
membrane [22,23]. This is associated with an impairment of
autophagy that exacerbates the myofiber dysfunction, as defective
mitochondria and proteins are not adequately cleared [21,24].
Together, these defects lead to myofiber apoptosis and muscle
wasting, which are characteristic also of human muscles affected
by collagen VI mutations [22,24]. Recent studies revealed that not
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only the muscles but also the tendon and osteotendineous
junctions are affected in Col6a12/2 mice [25,26]. Further studies
suggested that alterations of the sarcolemma (the barrier and the
link between ECM and intracellular environment) may be also
involved in the myofiber phenotype caused by collagen VI
deficiency [27].
Despite these major advances, several questions remain to be
answered for a better understanding of the muscle-specific
metabolic and phenotypic alterations characteristic of collagen
VI myopathies. The aim of the study was to identify protein
changes in the skeletal muscle of Col6a12/2 mice. We selected
three different muscles (gastrocnemius, tibialis anterior and
diaphragm) as these muscles are differently affected in the animal
model [20] and in human collagen VI myopathies [8,13–19].
This study for the first time identifies and correlates alterations
in proteins involved in the metabolism and mechanotransduction
in three muscles of Col6a12/2 mice, a model of human collagen
VI myopathies. Our results identify cellular changes that explain
the dysregulation of Ca2+, force development impairment,
increased muscle-relaxation-time and fiber damage observed in
patients. The severity of these changes differs in the three muscles
(gastrocnemius,tibialis anterior,diaphragm) and correlates to




All the procedures involving animals and their care were
conducted in conformity with the institutional procedures in
compliance with national (D.L. No. 116, G.U. Suppl. 40, Feb. 18,
1992, Circolare No. 8, G.U., 14 Luglio 1994) and international
regulations (EEC Council Directive 86/609, OJ L 358, 1 DEC.12,
1987; NIH Guide for the Care and use of Laboratory Animals,
U.S. National Research Council, 1996).
Mouse procedures were approved by the Ethics Committee of
the University of Padova and authorized by the Italian Ministry of
Health. (Permit Number: 22675). The animals were anesthetized
before sacrifice and all efforts were made to minimize suffering.
Mice and Sample Collection
All experiments were performed in 6-month-old Col6a12/2
(collagen VI null) mice and Col6a1+/+ (wild-type control) mice in
the same inbred C57BL/6NCrl strain. Four male mice per group
were used. Since previous studies demonstrated the absence of
specific phenotypic differences between male and female collagen
VI null mice [22], in the present study we have used only males.
Mice were housed in individual cages in an environmentally
controlled room (23uC, 12-h light-dark cycle) and provided with
food and water ad libitum. Animals were sacrified and gastrocne-
mius, tibialis anterior and diaphragm muscles were removed and
immediately frozen in liquid nitrogen, ground in a dry ice-cooled
mortar and stored at 280uC.
Proteomic Analysis
Two-dimensional difference in gel electrophoresis (2D-
DIGE). Protein labeling, 2D-separation and analysis were
performed exactly as previously described [28]. The adopted 3–
10 non linear pH gradients enable separation of protein isoforms
in the first dimension, providing a detailed pattern of the muscle
proteome. The proteomic profiles of gastrocnemius, tibialis
anterior and diaphragm muscles of Col6a12/2 mice were
compared with their correspondent controls. Statistically signifi-
cant differences of 2D-DIGE data were computed by Student’s t-
test (p,0.01). False discovery rate (FDR) was applied as a multiple
test correction in order to keep the overall error rate as low as
possible. Power analysis was conducted on statistically changed
spots, and only spots that reached a sensitivity threshold.0.8 were
considered as differentially expressed.
Protein identification by MALDI-TOF and ESI mass
spectrometry. For protein identification, semi preparative gels
were loaded with unlabelled sample (400 mg per strip); electro-
phoretic conditions were the same as 2D-DIGE, and gels were
stained with a total-protein fluorescent stain (Deep purple, GE
Healthcare). Image acquisition was performed using a Typhoon
9200 laser scanner. Spots of interest were excised from gel using
the Ettan spot picker robotic system (GE Healthcare), destained in
50% methanol/50 mM ammonium bicarbonate (AMBIC) and
incubated with 30 ml of 6 ng/ml trypsin (Promega) dissolved in
10 mM AMBIC for 16 hours at 37uC. Released peptides were
subjected to reverse phase chromatography (Zip-Tip C18 micro,
Millipore), eluted with 50% acetonitrile/0,1% trifluoroacetic acid.
Peptides mixture (1 ml) was diluted in an equal volume of 10 mg/
ml a-cyano-4-hydroxycinnamic acid matrix dissolved in 70%
acetonitrile/30% citric acid and processed on a Ultraflex III
MALDI-ToF/ToF (Bruker Daltonics) mass spectrometer. Mass
spectrometry was performed at an accelerating voltage of 20 kV
and spectra were externally calibrated using Peptide Mix
calibration mixture (Bruker Daltonics); 1000 laser shots were
taken per spectrum. Spectra were processed by FlexAnalysis
software v. 3.0 (Bruker Daltonics) setting the signal to noise
threshold value to 6 and search was carried out by correlation of
uninterpreted spectra to Rodentia entries (133347 sequences) in
NCBInr 20100918 (11833178 sequences; 4040378175 residues).
The significance threshold was set at p-value ,0.05. No mass and
pI constraints were applied and Trypsin was set as enzyme. One
missed cleavage per peptide was allowed and carbamidomethyla-
tion was set as fixed modification while methionine oxidation as
variable modification. Mass tolerance was set at 30 ppm for MS
spectra. To confirm protein identification, a MS/MS spectrum
was collected by Ultraflex III MALDI-ToF/ToF (Bruker Dal-
tonics) mass spectrometer, as acceptance criterium. Spectra were
searched against the database using BioTools v. 3.2 (Bruker
Daltonics) interfaced to the on-line MASCOT software, which
utilizes a robust probabilistic scoring algorithm. The significance
threshold was set at p-value ,0.05. One missed cleavage per
peptide was allowed and carbamidomethylation was set as fixed
modification while methionine oxidation as variable modification.
Mass tolerance was set at 30 ppm and 0.5 Da for peptide and
MS/MS fragment ion respectively.
In cases where this approach was unsuccessful, additional
searches were performed using ESI-MS/MS. MS/MS spectra
were recorded using a HCT Ultra mass spectrometer (Bruker
Daltonics) interfaced to an EASY-nLC chromatograph (Proxeon).
The samples were dissolved in 0.1% aqueous formic acid, injected
onto a 0.0756100mm EASY-Column (Proxeon), and eluted with
an acetonitrile/0.1% formic acid gradient (from 5 to 50% ACN).
The capillary voltage was set to 21600 V, and data-dependent
MS/MS acquisitions were performed on precursors with charge
states of 2, 3 or 4 over a survey mass range of 300–1500. The
collision gas was helium. Proteins were identified by correlation of
uninterpreted MS/MS to Rodentia entries in NCBInr, using
MASCOT software. No mass and pI constraints were applied and
Trypsin was set as enzyme. One missed cleavage per peptide was
allowed, and the precursor and fragment ion tolerance window
was set to 0.3 Da. Carbamidomethylation of cysteine was set as
fixed modification, whereas methionine oxidation as variable
modification.
Proteomic Changes in ColVI Deficient Mice Muscles
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Figure 1. Histograms of differentially expressed metabolic proteins in muscles of Col6a12/2 versus wild-type controls. Histograms of
differentially expressed proteins in gastrocnemius (black bars), tibialis anterior (grey bars) and diaphragm (white bars) muscles. Isoforms of proteins
significantly altered (Student’s T-test, p,0.01) are expressed as % of spot areas variation in Col6a12/2 versus wild-type controls. Panel A: energy
transfer and glycolysis and glucose metabolism; panel B: TCA cycle, respiratory chain and ATP production; panel C: aminoacid and lipid metabolism.
(Ckm: muscle creatine kinase; Ak1: adenylate kinase isoenzyme 1; Pgm2: phosphoglucomutase 2; Aldoa: fructose-bisphosphate aldolase A; Tpi1:
triosephosphate isomerase 1; Pgam2: phosphoglycerate mutase 2; Eno1: enolase 1 (alpha); Eno3: enolase 3 (beta muscle); Dlat: dihydrolipoyllysine-
residue acetyltransferase; Pkm2: pyruvate kinase isozymes M1/M2; Pdhb: pyruvate dehydrogenase (lipoamide) beta; Gapdh: glyceraldehyde-3-
phosphate dehydrogenase; Aco2: aconitase 2; Idh3a: isocitrate dehydrogenase [NAD] subunit alpha; Dlst: dihydrolipoamide S-succinyltransferase;
Sdha: succinate dehydrogenase complex, subunit A; Fh: fumarate hydratase 1; Mdh1: cytosolic malate dehydrogenase; Oat: ornithine
aminotransferase; Ogdh: 2-oxoglutarate (a-ketoglutarate) dehydrogenase; Ndufs3: NADH dehydrogenase (ubiquinone) iron-sulfur protein 3; Ndufs1:
NADH dehydrogenase (ubiquinone) Fe-S protein 1; Uqcrc1: ubiquinol-cytochrome-c reductase complex core protein I; Atp5b: ATP synthase, H+
transporting mitochondrial F1 complex, beta subunit; Atp5a: ATP synthase subunit alpha; Ivd: isovaleryl-CoA dehydrogenase; Ech1: delta (3,5)-
delta(2,4)-dienoyl-CoA isomerase; Apoa1: Apolipoprotein A-I; Pcca: propionyl-CoA carboxylase alpha chain; Glud1: glutamate dehydrogenase 1;
Aldh4a1: delta-1-pyrroline-5-carboxylate dehydrogenase; Fabp3: fatty acid-binding protein).
doi:10.1371/journal.pone.0056716.g001
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Immunoblotting
Protein extracts (50 mg) from pooled Col6a12/2 and control
muscles were loaded in triplicate and resolved on 6%, 10% and
12% polyacrylamide gels, according to protein molecular weight.
Blots were incubated with rabbit or goat polyclonal primary
antibodies (Cell Signaling Technology and Santa Cruz Biotech-
nology) as follows: anti-TN-C (1:500), anti-ROCK1 (1:500), anti
PI3K (1:1000), anti FAK (1:1000), anti-PPARc (1:1000), anti-
PPARa (1:1000), anti-PPARb (1:1000), anti-Sirt1 (1:1000), anti-
Sirt3 (1:1000), anti-FASN (1:1000), anti-IDH1 (1:1000), anti-
IDH2 (1:1000) and anti b-tubulin (1:1000). To confirm 2D-DIGE
data, 15% of differential expressed proteins were validated by
Immunoblotting. Blots were incubated with polyclonal primary
antibodies (as shown in Fig. S1) as follows: anti-PKM2 (1:1000),
anti-VDAC1 (1:1000), anti-ALDOA (1:1000) and anti-UQCRC1
(1:1000) for gastrocnemius; anti-PKM2, anti-ACO2 (1:1000), anti-
SDHA (1:1000) and anti-ATP5B (1:1000) for tibialis anterior; anti-
PKM2, anti-CA3 (1:2000), anti-ALDOA and anti-ATP5B for
diaphragm. After washing, membranes were incubated with anti-
rabbit (GE Healthcare) or anti-goat (Santa Cruz Biotechnology)
secondary antibodies conjugated with horseradish peroxidase.
Signals were visualized by chemiluminescence using the ECL Plus
detection kit. An image analysis system (Image Quant TL,
Molecular Dynamics) was performed followed by statistical
analysis (Student’s t-test, p,0.05).
Pyruvate Assay
Pyruvate concentration was determined by a colorimetric assay
measured at 570 nm (Sigma, cat.# MAK071) proportional to the
pyruvate present.
Enzymatic Assays
Citrate synthase (CS) was analyzed by a spectrophotometric
assay (Sigma, cat.# CS0720). NADH dehydrogenase activity
(complex I) was analyzed by a spectrophotometric assay as
described previously [29] and dehydrogenase activity (complex II)
was analyzed by a colorimetric-continuous method as described
previously [30].
Electron Microscopy
Samples were fixed with 2% glutaraldehyde in Hepes 0.2 M
(pH 7.4), in 2% OsO4, buffered with 0.1 sodium cacodylate. The
specimens were washed in distilled water, stained with 2%
aqueous uranyl acetate, dehydrated in alcohol and embedded in
Epon resin. Thin sections were cut with a Leica EM UC6
ultramicrotome (Leica Microsystems, Vienna, Austria). EM
images were acquired from thin sections using a FEI Tecnai-12
electron microscope (FEI, Eindhoven, Netherlands) equipped with
a VELETTA CCD digital camera (Soft Imaging Systems GmbH,
Munster, Germany).
Results
Gastrocnemius, Tibialis Anterior and Diaphragm Muscles:
Proteomic Analysis
The proteomic profiles of the three muscles from Col6a12/2
mice were compared with the corresponding controls. Among the
differentially expressed proteins, a total of 76, 66 and 65 changed
spots were identified in the gastrocnemius, tibialis anterior and
diaphragm, respectively. Histograms of differentially expressed
proteins are shown in Fig. 1 (panels A–C), Fig. 2 (panel A) and Fig.
S2. A representative proteomic map (see Fig. S3) and the
identification UniProtKB accession (AC) numbers from the three
Figure 2. Histograms of proteomic results and Immunoblotting
of cytoskeletal proteins. Panel A: histograms of structural and
cytoskeletal proteins differentially expressed in gastrocnemius (black
bars), tibialis anterior (grey bars) and diaphragm (white bars) muscles.
Proteins significantly altered (Student’s t-test, p,0.01) are expressed as
% of spot volume variation in Col6a12/2 versus wild-type. (Mybph:
myosin binding protein H, Mybpc3: myosin binding protein c; Gsn:
gelsolin; Vim: vimentin; Actc1: actin, alpha cardiac muscle 1; Des:
desmin; Myoz1: myozenin1; Cryab: alpha-crystallin B chain; Capzb:
capping protein (actin filament) muscle Z-line, beta isoform; Tpm1:
tropomyosin 1 alpha chain; Tpm2: tropomyosin 2 beta chain; Ywhag:
14-3-3 protein gamma; Tnni2: troponin I, fast skeletal muscle; Myl1:
myosin A1 catalytic light chain; Mylpf: myosin light chain, phosphor-
ylatable, fast skeletal muscle; Pvalb: parvalbumin; Tnnt3: troponin T, fast
skeletal muscle). Panel B: histograms and representative immunoblot
images of TN-C, FAK and ROCK1 in gastrocnemius, tibialis anterior and
diaphragm of Col6a12/2 and wild-type mice (n = 4; mean 6 S.D.;
Student’s T-test).
doi:10.1371/journal.pone.0056716.g002
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muscles are shown in supplementary material together with
peptide mass fingerprint (PMF) and Liquid Chromatography/
Mass Spectrometry (LC-MS/MS) data (see Table S1 and Data
S1). The main alterations identified can be grouped as metabolic
or structural/contractile.
Muscle Metabolism
The metabolic profile of each muscle was analyzed using
proteomics, enzymatic assays and immunoblottings. The identified
proteins are sub-grouped into energy transfer, glycolysis, anaerobic
metabolism, oxidative metabolism, respiratory chain, and amino
acid and lipid metabolism.
Energy transfer: proteomics (Fig. 1, panel A;
Fig. 3). Creatine kinase (M-CK) and adenylate kinase-1 (Ak1)
are essential mediators for cellular energetic and metabolic
signaling processes in tissues characterized by high and sudden
increases of energy demand, such as skeletal muscle. M-CK and
Ak1 were decreased in the three Col6a12/2 muscles, suggesting
that the cellular ability to maintain ATP turnover, under muscle
functional load, is reduced.
Glycolysis: proteomics (Fig. 1, panel A; Fig. 3). In
gastrocnemius, phosphoglucomutase 2 (Pgm2), which intercon-
verts glucose-1-P to glucose-6-phosphate, was increased. Most of
the proteins involved in the glycolytic pathway were decreased
(Fig. 1, panel A and Fig. 3; fructose biphosphate aldolase A, Aldoa;
triosephosphate isomerase, Tpi1; phosphoglycerate mutase,
Pgam2; and enolase, Eno3), with the exception of pyruvate kinase
M1/M2 isozymes (Pkm2) that were increased. Two subunits of
pyruvate dehydrogenase complex were changed: dihydrolipoylly-
sine-residue acetyltransferase (Dlat) was decreased, while pyruvate
dehydrogenase lipoamide beta (Pdhb) was increased.
In tibialis anterior, the glycolytic proteins were overall decreased
(Fig. 1, panel A and Fig. 3; Aldoa; Tpi1; Gapdh; Eno1; Eno3 and
Pkm2), with the exception of Pdhb that was increased.
In diaphragm, the glycolytic proteins were all decreased, except
Dlat that was unchanged compared with its control.
TCA cycle and associated metabolic substrates:
proteomics (Fig. 1, panel B; Fig. 3) and pyruvate assay
(Fig. 4, panel A). In gastrocnemius, proteins of the TCA cycle
were overall increased (Aconitase 2, Aco2; and Isocytrate
dehydrogenase, Idh3a - which together enhance the production
of a-ketoglutarate from citrate; dihydrolipoamide S-succinyltran-
ferase, Dlst - involved in the lipoic/dihydrolipoate antioxidant
redox balance; the subunit A of the succinate dehydrogenase
complex, Sdha; and fumarate hydratase 1, Fh). Also the cytosolic
malate dehydrogenase Mdh1 (a protein involved in the malate-
aspartate shuttle that transfers reducing equivalent, produced by
glycolysis, from cytoplasm to mitochondria and viceversa) was
increased. Conversely, ornithine aminotransferase (Oat), a mito-
chondrial enzyme that catalyzes the reversible inter-conversion of
ornithine and proline, was decreased. In this reaction, glutamate
acts as the amine donor for Oat, forming a-ketoglutarate and in
the reverse direction, a-ketoglutarate accepts the amine group,
forming glutamate and leading to the ultimate conversion of
proline to ornithine. The decrease in Oat suggests an attempt of
the gastrocnemius muscle to control energy balance.
In tibialis anterior, all the proteins of the TCA cycle were
increased (Aco2; Idh3a; a-ketoglutarate dehydrogenase, Ogdh;
Dlst and Sdha), as well as cytosolic malate dehydrogenase (Mdh1).
In diaphragm, a limited number of proteins of the TCA cycle
(Idh3a, Ogdh, Dlst) and Mdh1 were decreased.
The proteomic analysis of gastrocnemius and tibialis anterior of
Col6a12/2 mice (identified in the energy transfer, glycolysis and
TCA cycles) suggests that the overall decrease of glycolysis is
compensated by an increase of Pkm2 (specifically for gastrocne-
mius) and Pdhb (for both muscles) to sustain the activity of
pyruvate dehydrogenase complex (PDH). The latter, associated
with an increase in a-ketoglutarate complex (e.g. Ogdh, Dlst) and
IDH3, could support the activity of the TCA cycle. These results
also show that gastrocnemius appears less impaired at the
metabolic level than tibialis anterior.
The proteomic results obtained in the diaphragm indicate a
decreased flux in glycolysis, PDH complex, IDH3, and a-
ketoglutarate dehydrogenase complex, suggesting a severe meta-
bolic imbalance. The decrement of TCA cycle enzymes suggests
that the excess of citrate not utilized by the TCA cycle could be
exported to the cytosol to sustain the synthesis of lipids.
The pyruvate concentrations detected in the three Col6a12/2
muscles support the proteomic results. The concentration of
pyruvate was increased in gastrocnemius, decreased in tibialis
anterior and not detectable in diaphragm compared with the
corresponding wild-type control samples. The results suggest that
in Col6a12/2 gastrocnemius, pyruvate was generated partially by
glycolysis and by the malate/aspartate shuttle. In the Col6a12/2
tibialis anterior, where the downregulation of glycolysis was more
pronounced, pyruvate production was reduced compared to
control. In Col6a12/2 diaphragm, glycolysis was blunted and the
malate/aspartate shuttle was not finalized to pyruvate production,
resulting in undetectable pyruvate levels (Fig. 4, panel A).
Respiratory chain and ATP production: proteomics
(Fig. 1, panel B and Fig. 3) and enzymatic activities (Fig. 4
and Fig. 3). In gastrocnemius, an overall increase of respiratory
chain proteins (NADH dehydrogenase ubiquinone iron sulfur 3 -
Ndufs3 of complex I; ubiquinol-cytochrome c reductase core
protein I, Uqcrc1 of complex III) and of ATP synthase (beta Atp5b
and alpha Atp5a) were detected. In tibialis anterior and
diaphragm, an overall increase in the proteins of the respiratory
chain (Ndufs3 and Ndufs1; Uqcrc1; Atp5b and Atp5a) was
detected.
The enzymatic activities of citrate synthase (CS), complex I and
complex II in the three muscles of Col6a12/2 mice and of the
corresponding wild-type controls (Fig. 4, panels B-D) were
assessed. The CS activity was not significantly changed in the
three muscles, whereas NADH dehydrogenase activity (complex I)
and succinate dehydrogenase activity (complex II) were increased
in gastrocnemius and tibialis anterior, although complex II did not
reach statistical significance in the latter case. These results
confirm the proteomic results and further suggest that gastrocne-
mius and tibialis anterior of Col6a12/2 mice are attempting to
maintain the energetic homeostasis by increasing complexes I and
II activities. On the other hand, in the Col6a12/2 diaphragm, the
activity of complex I was similar to wild-type, while the activity of
complex II was decreased. These results support the proteomic
results and suggest that an energetic imbalance is occurring in this
muscle.
Aminoacid and lipid metabolism: proteomics (Fig. 1,
panel C; and Fig. 3) and immunoblotting (Fig. 5). In
gastrocnemius, three enzymes involved in the aminoacid and lipid
metabolism (isovaleryl-CoA dehydrogenase, Ivd; d(3,5)-dienoyl
CoA isomerase, Ech1-a mitochondrial NAD+ dependent dehy-
drogenase involved in fatty acid metabolism; and apolipoprotein
A-I, Apoa1) were decreased. Two enzymes mainly involved in
catabolism (propionyl-CoA carboxylase alpha chain, Pcca -
essential for the catabolism of valine and isoleucin aminoacids
and odd-chain fatty acids; and glutamate dehydrogenase 1, Glud1,
which functions in both the synthesis and the catabolism of
glutamate) were increased.
Proteomic Changes in ColVI Deficient Mice Muscles
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In tibialis anterior, a decrease in Ivd and an increase of d-1-
pyrroline-5-carboxylate dehydrogenase (Aldh4a1, an enzyme
which converts pyrroline-5-carboxylate to glutamate) and of fatty
acid binding protein 3 (Fabp3, a fatty acid transporter and
scavenger of fatty acids peroxides) [31–33] were observed.
In diaphragm, the only proteomic change was a decrease in
Fabp3, suggesting a decrease in the lipid transport and scavenging
of lipid peroxides.
To further support the results observed by proteomics, the
profile of the fatty acid synthase (FASN) protein was monitored in
the three muscles of the Col6a12/2 and compared with the
corresponding wild-type controls (Fig. 5, panel A).
In gastrocnemius and tibialis anterior, FASN was undetectable
both in Col6a12/2 and in wild-type controls, whereas in the
diaphragm the FASN level was significantly increased compared
with the corresponding control (Fig. 5, panel A). This increase was
associated with an accumulation of lipid droplets in the tissue
(Fig. 5, panel B).
The peroxisome proliferator-activated receptors (PPARs) and
peroxisome proliferator-activated receptor gamma coactivator-1-
alpha (PGC1a), two master regulators of mitochondrial biogenesis,
respiration and adipocyte differentiation, were analyzed in the
three muscles of Col6a12/2 mice and compared with the
corresponding wild-type muscles. PPARc, a regulator of adipocyte
differentiation [34], was decreased in the gastrocnemius and
tibialis anterior and unchanged in diaphragm (Fig. 5, panel C).
PPARb, involved in fatty acid metabolism and inflammation
[35,36], was significantly increased in the diaphragm only (Fig. 5,
panel C). PPARa, a key player in fatty acid oxidation, lipid and
lipoprotein metabolism and oxidative stress [37], and PGC1a were
unchanged in gastrocnemius and diaphragm, whereas they were
increased in tibialis anterior (Fig. 5, panel C and D).
Two de-acetylase enzymes, sirtuin 1 (SIRT1) and sirtuin 3
(SIRT3), were analyzed to better characterize the potential
dysmetabolism observed in the three muscles. Sirtuins were
quantified in the three muscles of Col6a12/2 mice and compared
with correspondent wild-type muscles. SIRT1, induced by NAD+,
regulates metabolism by repressing glycolytic genes [38,39] and
induces DNA repair [40]. In gastrocnemius, SIRT1 did not
change, in the tibialis anterior it was slightly increased (but not to
statistically significant levels), while in diaphragm it was signifi-
cantly increased (Fig. 5, panel E). These results suggest that the
decrease in Gapdh (observed in tibialis anterior and diaphragm)
and the decrease of Pdhb (observed in diaphragm) may modulate
the NAD+/NADH ratio, resulting in SIRT1 overexpression.
SIRT3 acts as a positive modulator of fatty acid oxidation [41]
and TCA cycle [42,43] and displays a protective role against
oxidative damage [44–46]. SIRT3 was increased in gastrocnemi-
us, while it did not change in tibialis anterior and diaphragm
(Fig. 5, panel E).
The expression of FASN, PPARs, PGC1a and sirtuins in the
three muscles confirms the proteomic results.
Metabolic (citrate) refueling (Fig. 3 and 6):
immunoblottings. In the absence of glucose, glutamine is the
major substrate available to the cells [47]. In skeletal muscle,
glutamine can act as a nitrogen donor in the synthesis of proteins
and nucleosides [48]. It can also be converted to a-ketoglutarate,
which can anaplerotically support the tricarboxylic acid (TCA)
cycle or be reductively transformed by cytosolic IDH1 to generate
citrate [49–51].
Isocitrate dehydrogenases (IDHs) reversibly catalyze oxidative
decarboxylation of isocitrate to a-ketoglutarate (a-KG) [47,52]
(Fig. 6 panel B). IDH1 (NADP+-dependent) functions in the
cytosol and peroxisomes, and its activity becomes predominant
under hypoxia for de novo lipogenesis [47]. IDH2 (NADP+-
dependent) and IDH3 (NAD+-dependent) localize in the mito-
chondria, where they are positively modulated by the mitochon-
drial matrix Ca2+ concentration. IDH3 is allosterically regulated
and operates in the oxidative direction. Proteomic results indicated
an increase of IDH3 in gastrocnemius and tibialis anterior and a
decrease in diaphragm, whereas IDH1 and IDH2 were undetect-
able in Col6a12/2 compared to wild-type muscles.
Quantitative immunoblottings show that IDH1 was overex-
pressed, while IDH2 remained unchanged in the three muscles
(Fig. 6, panel A).
These results suggest that IDH1 sustains the synthesis of
glutamine through a-ketoglutarate conversion in gastrocnemius
and tibialis anterior of Col6a12/2 mice. In diaphragm, reductive
carboxylation of a-ketoglutarate sustains, via IDH1, the lipogenic
citrate synthesis. Furthermore, the observed increase in FASN
confirms that citrate is finalized to de novo lipogenesis [47,53,54].
Muscle metabolism: summary of changes. In Col6a12/2
gastrocnemius, the glycolytic enzymes are overall decreased,
whereas the TCA cycle enzymes are increased. Furthermore, the
increase of Glud1 and IDH1, which generates a-ketoglutarate, is
finalized to glutamine production. The TCA cycle activity is
associated with an increased respiratory chain activity and SIRT3,
resulting in an increased energy production and possibly in at least
partial activation of defense mechanisms against oxidative stress.
In Col6a12/2 tibialis anterior, glycolytic enzymes are decreased,
but energy production is still sustained by the TCA cycle.
Conversely, IDH1 and Aldh4a1, which sustain glutamine
production, are increased. Furthermore, also in tibialis anterior
the respiratory chain activity is overall increased. However, the
specific increases in PPARa and PGC1a suggest that tibialis
anterior promotes cellular metabolism and muscle lipid oxidation.
In Col6a12/2 diaphragm, glycolysis is blunted, differently from
gastrocnemius and tibialis anterior. TCA cycle and respiratory
chain are also decreased, forcing IDH1 to reductively generate
lipogenic citrate. The maintenance of CS activity and the decrease
of cytosolic Mdh1 suggest that citrate is exported to the cytosol,
possibly due to the TCA cycle impairment. Furthermore, due to
Mdh1 decrease, oxaloacetate, which cannot re-enter into mito-
chondria, is reduced to a-ketoglutarate. The latter acts as IDH1
substrate (see Fig. S4), resulting in abnormal fatty acid synthesis,
which is consistent with the increase in FASN and lipid droplets.
The overexpression of SIRT1 and the increase of PPARb
(associated with the decrease in Fabp3) appear unable to
counteract the detrimental lipid signaling leading to cell death.
Structural and contractile proteins: proteomics (Fig. 2A;
Fig. 7) and immunoblottings (Fig. 2B; Fig. 7). In Col6a12/2
gastrocnemius, proteins involved in cytoskeletal stabilization were
increased (fetal myosin binding protein H, Mybph; myosin binding
protein C, Mybpc3; gelsolin, Gsn; vimentin, Vim; alpha cardiac
actin, Actc1; desmin, Des; myozenin 1, Myoz1; and alpha
crystallin B chain, Cryab). Conversely, other structural and
Figure 3. Schematic representation of metabolic enzymes deregulated in gastrocnemius, tibialis anterior and diaphragm muscles.
Grey rectangles contain gene names and arrows indicate the protein trend in gastrocnemius, tibialis anterior and diaphragm, respectively. The arrows
direction indicates up- and down-regulation, the thickness the % of spot variation. = /Q or = /q indicate the differential expression of isoforms of
the same protein in a given muscle (for details see Table S1).
doi:10.1371/journal.pone.0056716.g003
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Figure 4. Results of enzymatic assays. Histograms showing pyruvate quantitation (panel A), citrate synthase enzymatic activity (panel B), NADH
dehydrogenase (complex I) enzymatic activity (panel C) and succinate dehydrogenase (SDH, complex II) enzymatic activity (panel D) in
gastrocnemius, tibialis anterior and diaphragm muscles from Col6a12/2 and wild-type (wt) mice.
doi:10.1371/journal.pone.0056716.g004
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contractile proteins were decreased (actin capping protein A,
Capzb; tropomyosin 1 alpha and beta chains, Tpm1 and Tpm2;
14-3-3 protein gamma, Ywhag; troponinin I fast, Tnni2; myosin
A1 catalytic light chain, Myl1; myosin light chain phosphoryla-
table fast isoforms, Mylpf), suggesting instability of actin filament,
muscle fiber damage, force development impairment, deregulation
of Ca2+ handling, and increased muscle relaxation time (decrease
of parvalbumin, Pvalb).
In Col6a12/2 tibialis anterior, several proteins were decreased
(Mybpc3; Capzb; Myoz1; Tpm1; Tnni2 and Pvalb), suggesting an
alteration in actin filaments polymerization, muscle fiber damage,
deregulation of Ca2+ handling, and increased muscle relaxation
time (decrease of parvalbumin, Pvalb).
Figure 5. Immunoblotting of proteins involved in lipid metabolism. Histograms and representative immunoblot images of FASN (panel A),
PPARc, a and b (panel C), PGC1-a (panel D), SIRT1 and SIRT3 (panel E) in gastrocnemius, tibialis anterior and diaphragm from Col6a12/2 and wild-type
mice (n = 4; mean 6 S.D.; Student’s T-test). Panel B: electron microscopy image showing lipid accumulation in the diaphragm of Col6a12/2 mice.
Black arrows show lipid droplets.
doi:10.1371/journal.pone.0056716.g005
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In Col6a12/2 diaphragm, only Mybpc3, a regulator of actin-
myosin interaction and remodeling, was increased and several
proteins mainly involved in the Ca2+ binding were decreased
(Capzb; Actc1; troponin T fast, Tnnt3; Myl1 and Pvalb). These
results suggest that deregulation of Ca2+ handling and instability of
the actin filament may play a predominant role in the diaphragm
impairment.
Figure 6. Immunoblotting and 2D-DIGE results on proteins involved in glutamate metabolism. Panel A: Histograms and representative
immunoblot images of IDH1 and IDH2 in gastrocnemius, tibialis anterior and diaphragm from Col6a12/2 and wild-type mice (n = 4; mean 6 S.D.;
Student’s T-test). Panel B: schematic representation of IDHs pathways. Grey and empty rectangles contain gene names of deregulated proteins
observed by 2D-DIGE and western blotting, respectively. Arrows indicate the protein trend in gastrocnemius (G), tibialis anterior (T) and diaphragm
(D). For 2D-DIGE, the arrows direction indicates up- and down-regulation, the thickness the % of spot variation. = /Q or = /q indicate the differential
expression of isoforms of the same protein in a given muscle. For western blotting, the arrows direction indicates the up- and down-regulation of
relative variation of Col6a12/2 versus control wild-type muscle.
doi:10.1371/journal.pone.0056716.g006
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The identified changes in structural and contractile proteins
suggest that signaling from the sarcomeres to muscle cell is altered,
albeit at a different extent, in the three muscles. Specific
immunoblotting assays were performed to further analyze muscle
changes induced by altered mechanotransduction (Fig. 2, panel B
and Fig. 7).
Tenascin C (TN-C) is a glycoprotein located in the area where
high mechanical forces are transmitted (e.g. at the myotendineous
junction) [55]; it provides de-adhesive properties and plays a
critical role in muscle injury repair [56–58]. In Col6a12/2
gastrocnemius, TN-C was decreased resulting in a possible
increase in matrix adhesion. Mybpc3, a regulator of actin-myosin
interaction and remodeling [59] and intermediate filament
proteins (Vim, Des, Cryab) were increased, suggesting a compen-
satory pathway in the sarcomere. In Col6a12/2 tibialis anterior
and diaphragm, TN-C was increased resulting in a possible
decrease of matrix adhesion.
Focal adhesion kinase (FAK) regulates focal adhesion turnover
and adhesion strength [60] and is essential for costamerogenesis
[61]. Costameres promote the alignment of myofibrils and anchor
myofibril Z-bands to the sarcolemma. Furthermore, Rho/
ROCK1 pathway promotes myosin contractility and mediates
reorganization of the actin cytoskeleton [62,63]. Focal adhesion
kinase (FAK) and Rho-associated protein kinase 1 (ROCK1) were
increased in the three Col6a12/2 muscles, further supporting
alterations of cytoskeletal tension and of mechanotransduction
(Fig. 7).
Muscle phenotype: summary of changes. In Col6a12/2
mice, gastrocnemius tends to stabilize the Z-line and the
costameric structure (described in Fig. 7, panel A and B) with
increase in Gsn, Vim, Actc1, Des, Myoz1 and Cryab), in an
attempt to adapt to the physical surrounding. However, despite
these compensatory mechanisms, Col6a12/2 gastrocnemius is
characterized by instability of actin filament, fiber damage,
impairment of force development, deregulation of Ca2+ handling
(e.g. decrease in Tnni2, Mylpf and Myl1 and increase in Mybph),
increased muscle relaxation time (decrease of Pvalb), abnormal
muscle elasticity (i.e. decrease in TN-C; increase in Mybpc3) and
altered cytoskeletal tension (i.e. increase in FAK and ROCK1-
Col6a12/2 tibialis anterior is characterized by changes in actin
filaments polymerization, presence of muscle fiber damage,
deregulation of Ca2+ handling (e.g. decrease in Capzb and
Tpm1), increase in muscle relaxation time (decrease of Pvalb),
abnormal muscle elasticity (i.e. increase in TN-C; decrease in
Mybpc3) and altered cytoskeletal tension (i.e. increase in FAK and
ROCK1).
Col6a12/2 diaphragm is characterized by more severe pheno-
typic changes in comparison with gastrocnemius and tibialis
anterior, with instability of actin filaments, deregulation of Ca2+
handling (e.g. decrease in Myoz1, Actc1, Myl1 and Pvalb),
increased muscle relaxation time (decrease of Pvalb), abnormal
muscle elasticity (i.e. increase in TN-C and Mybpc3) and altered
cytoskeletal tension.
Besides those discussed here, other proteins were altered in the
three Col6a12/2 muscles and the results are summarised in the
Supplementary Fig. S2.
Discussion
This study investigated protein alterations in three muscles
(gastrocnemius, tibialis anterior and diaphragm) of Col6a12/2
mice, a model of human collagen VI myopathies. These muscles
were selected since they are differently affected in Col6a12/2 mice
[20,21] and in human collagen VI myopathies [8,13–19]. The
Col6a12/2 mouse model is widely studied, as it resembles human
Bethlem myopathy and UCMD. Col6a12/2 mice display a
myopathic phenotype characterized by an early onset phenotype
and very slow progression [20]. Therefore, a single time-point (i.e.
6-month-old mice) was used, as this represents the most
characterized time-point for these mice [21,22]. A limitation of
the proteomic analysis is the inability to identify proteins in the
range of pico- to femtomoles. We have, at least partially, overcome
this limitation by performing immunoblotting and enzymatic
assays on specific proteins. This careful design enabled the
characterization of metabolic and structural protein alterations
in the three muscles, thus providing a broader understanding of
the pathological changes and of their connections to the
pathophysiology of the collagen VI myopathies.
Based on the results of this study, the gastrocnemius muscle of
Col6a12/2 mice is metabolically characterized by a slight
decrement of the glycolytic flux, compensated by an increase of
the TCA cycle, respiratory chain and SIRT3, resulting in an
increased energy production and at least a partial activation of
defense mechanisms against oxidative stress. The tibialis anterior
muscle of Col6a12/2 mice has an overall similar metabolic profile
to the gastrocnemius (except for the increase of SIRT3). However,
the specific increases of PPARa and PGC1a in Col6a12/2 tibialis
anterior suggest that this muscle compensates collagen VI
deficiency (and its concomitant mitochondrial deficit) with
increased biogenesis. At variance from gastrocnemius and tibialis
anterior, diaphragm is characterized by a blunted glycolytic flux,
TCA cycle and respiratory chain activity. This profile is associated
to an increased a-ketoglutarate production by IDH1, which
generates lipogenic citrate. Lipotoxicity and the resulting cell
death are further sustained by an increment of PPARb, triggering
detrimental lipid signaling, and of SIRT1, sensing NADH
imbalance and inhibiting glycolytic genes. Interestingly, metabolic
changes are not accompanied by a fiber type switch, as indicated
by the lack of changes in the myosin heavy chain (MyHC) isoforms
composition (see supplementary Fig. S5). These results are in
agreement with those of Irwin et al. [22] and suggest that, in
collagen VI deficiency, metabolic changes are caused by an altered
signal transduction and are not due to a change in fiber type
distribution which occurs in ageing or unloading processes [64,65].
We have provided the first analysis of the proteome of Col6a12/
2 mice, which documents a set of changes in proteins that are
involved in energy transformation, mitochondrial biogenesis and
Ca2+ homeostasis (troponin I fast, aldolase, enolase 3, triose
phosphate isomerase, creatine kinase, adenylate kinase 1, parval-
bumin, PPARs, PGC1a),associated with changes of proteins
involved in mechanotransduction at the myotendineous junc-
tion/costameric/sarcomeric level (TN-C, FAK, ROCK1). The
observed changes are specific for each muscle type, suggesting that
diaphragm is more impaired than tibialis anterior and gastrocne-
mius even before the onset of respiratory insufficiency.
Our results are in agreement with previous in vivo studies,
reporting that diaphragm presents a higher frequency of
degenerating fibers compared to other muscles in the Col6a12/2
animal model [20,21] and with respiratory insufficiency phenotype
observed in UCMD and BM patients [19].
The phenotypic changes of the three Col6a12/2 muscles
demonstrate that the structural changes do compromise biochem-
ical signaling (altered mechanotransduction), albeit to a different
extent. In the gastrocnemius muscle, the structural changes at the
thin filament level are balanced by the counteracting of de-
adhesion activities, the increment of z-line proteins and the
turnover of damaged fibers (Mybph increment). The energy
demand is sustained by an increased capacity of the TCA cycle
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Figure 7. Costameric schematization, immunoblotting and proteomic results of proteins involved in mechanotransduction. Panel A:
schematic representation of costameres and force transmission by ECM. The junction between cell matrix to the muscle cell is represented by
costameres which consist of a complex protein network that forms a physical attachment of the underlying, outer Z discs of the muscle cell to its
surrounding, stress-tolerant, ECM. These specialized sites occur over the entire sarcolemma, where the transmission of force is concentrated (black
arrows) from cells to ECM, along and perpendicularly to the tendon axis (dotted grey line) with the role of keeping sarcolemma aligned with nearby
contractile structures [79,80]. The absence of collagen VI would alter the signaling from the interstitial connective tissue to the muscle fiber and
Proteomic Changes in ColVI Deficient Mice Muscles
PLOS ONE | www.plosone.org 12 February 2013 | Volume 8 | Issue 2 | e56716
and by the oxidative production of a-ketoglutarate through IDH1.
In contrast, the tibialis anterior muscle and even more the
diaphragm muscle are unable to compensate for the specific
structural changes, resulting in a more severe phenotype, with
activation of lipid oxidation in tibialis anterior and activation of
FASN and cell death process in the diaphragm. Our results are in
agreement with the muscular changes reported in UCDM and
BM patients [14,15,18]. Previous studies have reported that
changes in mechanotransduction could result in (or at least
contribute to) various human muscular diseases [66]. However, as
far as we are aware, this is the first study describing alterations in
the mechanotransduction, which triggers reductive TCA cycle
leading in turn to lipogenic citrate production in a model of
muscular dystrophy. Changes in the ECM-integrin-costameric
system [67], a primary mechanical sensor of collagen VI
deficiency, transduce altered signals to muscle fibers resulting in
sarco/endoplasmic reticulum stress [22,68], Ca2+ deregulation
[69] and activation of signaling pathways including ROCK1 and
FAK [60,70,71]. Altered mechanotransduction impacts on the
localization of the protein-complexes and their correct functions,
resulting in energy impairment. The changes in muscle pheno-
types are strictly associated with the metabolic impairment (i.e. a
decrease in glycolytic enzymes and altered TCA cycle, with
diaphragm.tibialis anterior.gastrocnemius), as the precise sub-
cellular localization of metabolic proteins (e.g. glycolytic enzymes
and M-CK in the thin filament and Z-line) is critical for energy
production and utilization [72–74].
Our results also suggest that muscle mass and tendon
(myotendineous junction) ratio and the muscle morphology play
a critical role in the selective response of individual muscles.
Gastrocnemius, characterized by a high muscle mass and tendon
ratio, is metabolically and structurally less impaired in Col6a12/2
mice than tibialis anterior and diaphragm. Tibialis anterior has a
lower muscle mass and tendon ratio compared with gastrocnemius
(but higher than diaphragm) and in Col6a12/2 mice is metabol-
ically and structurally more impaired than gastrocnemius and less
impaired than diaphragm. Furthermore, the mass to tendon ratio
appears to be correlated with the incidence of centrally nuclei
fibers in different muscles (triceps,femoralis,external respiratory
muscles,tibialis,diaphragm) [20,21], the diaphragm being the
most affected muscle.
Finally, diaphragm is the most impaired muscle in Col6a12/2
mice. Importantly, tendons were reported to actively participate in
mechanotransduction [75,76] and to be dysfunctional in Col6a12/
2 mice [25].
Gastrocnemius and tibialis anterior appear to counteract the
biochemical changes induced by improper myofibril alignment, by
increasing their capacity of energy transformation, thus balancing
the reduction of the glycolytic flux and Ca2+ overload, and
counteracting lipid signaling by recruiting all possible energy
sources to produce NADH and ATP. This may result in buffering
Ca2+ that, otherwise, cannot be taken up properly by the
sarcoplasmic reticulum, as indicated by the decrement of
parvalbumin [77,78]. The oxidative production of energy,
observed in gastrocnemius and tibialis anterior, results in the
generation of intermediates that sustain the anabolic substrates
production (Fig. S4, panel A). By contrast, in diaphragm, the
myofibrils distribution and the higher contribution of the tendon,
which expresses TN-C, exacerbates the mechanotransduction
defects, leading to lipid signaling. The resulting lipotoxicity
become predominant suggesting that the absence of collagen VI
causes ECM structural changes, generating an improper align-
ment of myofibrils that impacts both on cell metabolism and
mitochondria as final targets (Fig. S4, panel B).
Overall Conclusions
Our study analyzed the muscle protein alterations in a mouse
model of human collagen VI myopathies. Our study for the first
time demonstrates the following points 1) In Col6a12/2 mouse
model, the main changes identified can be grouped as metabolic
and structural/contractile. 2) The metabolic changes occur at a
cellular, not only at mitochondrial level. The gastrocnemius and
tibialis anterior muscles of Col6a12/2 mice are characterized by an
increased TCA cycle, respiratory chain and IDH1, whereas
Col6a12/2 diaphragm is characterized by an increased FASN and
activation of lipogenic citrate production through IDH1. 3)
Overall, the metabolic changes are associated with the changes
in muscle phenotype, generating an altered mechanotransduction.
4) Alterations in the mechanotransduction reveal that only a
limited number of proteins (FAK, troponin I fast, aldolase, enolase
3, triose phosphate isomerase, creatine kinase, adenylate kinase 1,
parvalbumin and IDH1) are similarly affected in all muscles
suggesting that they may represent the potential markers and
targets for pharmacological treatment. 5) The mass and tendon
(myotendineous junction) ratio and the muscle morphology play a
critical role in the severity of the muscle impairments.
Supporting Information
Figure S1 Validation of LC/MS/MS identified proteins
by immunoblotting. Immunoblotting of selected proteins
(identified with proteomic) in gastrocnemius (A), tibialis anterior
(B) and diaphragm (C) muscles from Col6a12/2 versus wild-type
pooled samples, normalized against b-tubulin (b-Tub). Pkm2:
pyruvate kinase isozymes M1/M2; Vdac1: voltage-dependent
anion-selective channel protein 1; Aldoa: fructose-bisphosphate
aldolase A; Uqcrc1: ubiquinol-cytochrome-c reductase complex
core protein I; Aco2: aconitase 2; Sdha: succinate dehydrogenase
complex, subunit A; Atp5b: ATP synthase, H+ transporting
mitochondrial F1 complex, beta subunit; Ca3: carbonic anhydrase
3.
(TIF)
Figure S2 Histograms of proteomics results of stress
proteins and others. Histograms of stress proteins and others
differentially expressed in gastrocnemius (black bars), tibialis
anterior (grey bars) and diaphragm (white bars) muscles. Isoforms
of proteins significantly altered (Student’s t-test, p,0.01) are
expressed as percent of spot volume variation in Col6a12/2 versus
wild-type. (Fgg: fibrinogen, gamma polypeptide; Mb: myoglobin;
Immt: inner membrane protein, mitochondrial; Phb: prohibitin;
Vdac1: voltage-dependent anion-selective channel protein 1;
Eif4a2: protein synthesis initiation factor 4; Selenbp1: Selenium-
tendon [1,2,4,81]. Panel B: Graphical representation of the muscle unit involved in mechanotransduction in which deregulated proteins are indicated.
For details see Table S1. Grey and empty rectangles contain gene names of deregulated proteins observed by 2D-DIGE and western blotting,
respectively. Arrows indicate the protein trend in gastrocnemius (G), tibialis (T) and diaphragm (D). For 2D-DIGE results, the arrows direction indicates
the up and down regulation, the thickness the % of spot variation, as described in ‘‘legend’’. = /Q or = /q indicate the differential expression of
isoforms of the same protein in a given muscle. For western blotting, the arrows direction indicates the up and down regulation of relative variation
of Col6a12/2 versus control muscle.
doi:10.1371/journal.pone.0056716.g007
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binding protein 1; Prdx3: peroxiredoxin-3; Hspd1: heat shock
protein 1; Ca2: carbonic anhydrase 2; Ca3: carbonic anhydrase 3;
Prdx1: peroxiredoxin-1; Sod1: superoxide dismutase [Cu-Zn];
Hspa8: heat shock protein 8; Hspb1: heat shock protein beta-1;
Prdx6: peroxiredoxin-6; Psma6: proteasome subunit, alpha type 6;
Pdia3: protein disulfide-isomerase A3).
(TIF)
Figure S3 Representative skeletal muscle 2D map.
Proteins separation was performed on pH 3–10 NL 24 cm IPG
strips in the first dimension and on 12%T-2.5%C PAGE gels in
the second dimension. The identified and statistically changed
spots in gastrocnemius, tibialis anterior and diaphragm of
Col6a12/2 vs. wild-type mice are indicated by numbers. The
protein names, the gene name and the AC number together with
MS data are listed in table 1S.
(TIF)
Figure S4 Schematic representation of the different a-
ketoglutarate fate in muscles from Col6a12/2 mice. The
direction of IDH1 reaction is controlled by alterations in TCA
cycle fluxes leading to the production of anabolic substrates for
gastrocnemius and tibialis anterior muscles (panel A), and
lipotoxicity for diaphragm muscle (panel B).
(TIF)
Figure S5 Myosin heavy chain isoforms composition.
SDS electrophoresis was performed on muscle samples using a
discontinuous buffer system with a 4% stacking gel (pH 6.8) and a
37% glycerol, 6%T constant concentration running gel (pH 8.8).
Samples were separated at 100 V, overnight. Gels were stained
with SYPRO Orange (Molecular Probe) and scanned using a
570 nm emission filter on Typhoon laser scanner. Protein band
quantification was achieved using Image Quant (Molecular
Dynamics) software. Individual samples were run in duplicate;
2 mg protein extract was loaded per lane. Differences between
groups were computed by Student’s t-test, the significativity level
being set at p,0.01. A two-tail F-test was applied in order to verify
the homoscedasticity of variances.
(TIF)
Table S1 Mass spectrometry data. Protein identifica-
tion in muscle tissue by PMF and MS/MS. The spot
number, the protein names, the gene name, the % of spot
variation and the AC number together with MS data are listed.
(PDF)
Data S1 Supplementary MS data. Representative MALDI-
ToF PMF spectra and MSMS sequence analysis from the
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